Program



Day 1

10:00 Start of Registration

10:45 WELCOME

GLOMERULAR DISEASES

11:00 A histopathologic overview of what was membranoproliferative glomerulonephritis once – Sanjeev Sethi
11:25 Membranous nephropathy-targeted therapy as new normality after detection of several antigens – Fernando Fervenza
11:50 Steroid sparing in ANCA-associated vasculitis – are we there yet? – Ulrich Specks
12:15 Management of proliferative glomerulonephritis with monoclonal immunoglobulin deposits – Ladan Zand

12:40 LUNCH BREAK

HYPERTENSION IN SPECIFIC SCENARIOS

13:50 Preeclampsia: old and novel concepts to improve outcome – Vesna Garovic
14:05 Cancer-therapy related hypertension – Sandra Herrmann
14:30 Thrombotic microangiopathies secondary to cancer therapies, infections, etc. – Meera Sridharan
14:55 Management of cardiovascular risk factors in nephrology and oncology – room for improvement? – Neeraj Dhaun

15:20 COFFEE BREAK

THROMBOSIS – FROM BENCH TO BEDSIDE

15:50 Cancer-associated thrombosis: Why do we believe that patients
require a different approach? – Cihan Ay
16:15 Anticoagulation in our dialysis population: yes, no, maybe? – An S. de Vriese
16:40 Mechanisms of thrombosis in cancer patients, transplant recipients and autoimmunity – Henri Versteeg
17:05 Bleeding complications and thrombotic events in transplantation – Hatem Amer

19:00 Faculty Dinner

Day 2

TRANSPLANTATION

09:00 Histology in transplant rejection – Banff and beyond – xyc
09:25 How does sequencing on a single-cell basis inform about prognosis of kidney transplant recipients? – Menna Clatworthy
09:50 TTV – an immunologic marker for transplant recipients, and also autoimmune patients and patients with malignancy? – Gregor Bond

10:15 COFFEE BREAK

SLE

10:45 Morbidity and mortality of patients with SLE and LN – Ali Duarte-Garcia
11:10 Current standard management of LN – Hans-Joachim Anders
11:35 Update in Lupus Nephritis Histopathology – why is it needed? – Ingeborg Bajema
12:00 Complications of SLE medication – Zoster, reduced fertility, fatigue, what else? – Laurent Arnaud

12:30 LUNCH BREAK

FUTURE THERAPIES & COMPLICATIONS OF INNOVATIVE THERAPIES

13:30 BiTE, CiTE, SMITE, TriKE, CART-BiTE, etc. – an overview of new therapeutic options in hematologic malignancies – Dominik Wolf
13:55 CAR-T cell therapy – past, present, and future – Andreas Mackensen
14:20 Hemophagocytic lymphohistiocytosis – an overview – Paul Graf La Rosée
14:45 Amyloidosis – Helen Lachmann

15:10 COFFEE BREAK

ONCOLOGY AND NEPHROLOGY IN COUNTRIES WITH LOW RESOURCES

15:30 Treating Hematologic Malignancies in a cost-restricted environment – Neil Littleton
15:55 Treating patients with kidney diseases in low and low to middle income countries – xyz

16:20 CLOSING REMARKS & END of the Meeting